Ritlecitinib Hits Primary Goals in Phase 3 Vitiligo Studies

Ritlecitinib (Litfulo, Pfizer) is showing promise in nonsegmental vitiligo, according to positive top-line results from two Phase 3 trials.

Ritlecitinib (Litfulo, Pfizer) is showing promise in nonsegmental vitiligo, according to positive top-line results from two Phase 3 trials.